Shots:

• The company has completed a P-I trial that assessed ALT-L9 vs Eylea in 28 patients in a ratio (1:1) with neovascular (wet) AMD. The trial was conducted at 4 major hospitals in Korea
• The safety & efficacy of ALT-L9 were similar to Eylea and the results showed similar improvement effects in BCVA and CST. The P-I results will support the design of the P-III study and provide a path to a shorter P-III trial
• Alteogen strengthens the competitiveness through global formulation and patents registration in the US- EU and Japan and filing of a process patent for PCT application

 ­ Ref: Businesswire | Image: Businesswire